New Agilent Target Enrichment Solution for Next-Generation DNA Sequencing Adds More Than 1,000 Disease Relevant Targets

TEVET key industry partner Agilent Technologies delivers a curated, annotated list of included genes, as well as evidence for disease relevance with SureSelect Clinical Research Exome V2—the first on the market! Researchers can discover and identify new disease-associated targets with an additional 1,099 disease-associated genes, over 75,000 splice sites of noncoding exons, over 12,000 previously reported deep intronic variants, and over 800 variants in promoter regions. These targets were identified through an exhaustive curation effort led by Emory University and the Children's Hospital of Philadelphia. Designed for clinical research laboratories, this new product delivers an efficient and cost-effective exome that can reach deep into targets that matter most in your research.

Contact a TEVET expert today to advance your clinical research to the highest level!

Read Press Release...